Humacyte, Inc. Proceeds from Issuance Initial Public Offering
Humacyte, Inc. (HUMA) reported Proceeds from Issuance Initial Public Offering of $98.00 million for the 6-month period ending 2020-12-31, per its 10-K/A filed 2021-05-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceInitialPublicOffering · last filed 2021-05-14
- Humacyte, Inc. proceeds from issuance initial public offering for the quarter ending 2020-12-31 was $0.00.
- Humacyte, Inc. proceeds from issuance initial public offering for the quarter ending 2020-09-30 was $98.00M.
| Period end | Proceeds from Issuance Initial Public Offering 3 month | Proceeds from Issuance Initial Public Offering 6 month |
|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K/A 6 month − 10-Q 3 month · filed 2021-05-14 | $98.00M 10-K/A · filed 2021-05-14 |
| 2020-09-30 | $98.00M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |